Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women
In conclusion, oestradiol contributes to altered antitumour effects of Zol observed between pre- and post-menopausal women. However, other immunological/microenvironmental factors are also likely to contribute to this phenomenon.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Allergy & Immunology | Clinical Trials | Endocrinology | Fibrosarcoma | Hormones | Men | Menopause | Reclast | Study | Women | Zometa